Innovent Biologics, Inc. (HKG:1801)
99.30
+4.65 (4.91%)
Aug 21, 2025, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 5,659 employees as of December 31, 2024. The number of employees increased by 787 or 16.15% compared to the previous year.
Employees
5,659
Change (1Y)
787
Growth (1Y)
16.15%
Revenue / Employee
1.77M HKD
Profits / Employee
-17.80K HKD
Market Cap
162.11B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5,659 | 787 | 16.15% |
Dec 31, 2023 | 4,872 | -422 | -7.97% |
Dec 31, 2022 | 5,294 | -274 | -4.92% |
Dec 31, 2021 | 5,568 | 2,289 | 69.81% |
Dec 31, 2020 | 3,279 | 1,297 | 65.44% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
BeOne Medicines | 11,000 |
Hansoh Pharmaceutical Group Company | 8,989 |
JD Health International | 3,564 |
Akeso | 3,035 |
Sino Biopharmaceutical | 24,379 |
WuXi Biologics | 12,575 |
CSPC Pharmaceutical Group | 21,400 |
Sichuan Kelun-Biotech Biopharmaceutical | 1,837 |
Innovent Biologics News
- 16 days ago - Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032 - PRNewsWire
- 5 weeks ago - Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma - PRNewsWire
- 5 weeks ago - ‘China’s Ozempic’ pioneer inks deal with JD Health for online distribution - South China Morning Post
- 7 weeks ago - Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide - Seeking Alpha
- 7 weeks ago - Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms - PRNewsWire
- 7 weeks ago - Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management - PRNewsWire
- 2 months ago - Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions - PRNewsWire
- 2 months ago - Neutral On Innovent Biologics: Hard To Justify Its Premium - Seeking Alpha